TP53 and prostate adenocarcinoma: While Donehower et al.’s work [39] explores the molecular pathways behind TP53 variations across multiple malignancies, our analysis reveals TP53 overexpression as a strong prognostic predictor, notably in prostate adenocarcinoma.